NKGen Biotech, Inc.
NKGN
$0.1275
$0.00151.19%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 66.23% | 74.32% | 68.76% | 83.83% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.79% | 22.40% | 21.61% | 21.80% | -- |
| Operating Income | -17.79% | -22.42% | -21.80% | -22.18% | -- |
| Income Before Tax | 13.89% | -196.08% | -180.60% | -210.12% | -- |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | 0.00% | -- |
| Earnings from Continuing Operations | 13.89% | -196.03% | -180.56% | -210.06% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.89% | -196.03% | -180.56% | -210.06% | -- |
| EBIT | -17.79% | -22.42% | -21.80% | -22.18% | -- |
| EBITDA | -18.72% | -23.59% | -22.97% | -23.37% | -- |
| EPS Basic | 51.55% | -52.60% | -56.81% | -78.94% | -- |
| Normalized Basic EPS | 26.55% | -67.82% | -50.39% | -73.11% | -- |
| EPS Diluted | 49.95% | -52.60% | -56.81% | -78.94% | -- |
| Normalized Diluted EPS | 28.92% | -67.82% | -50.39% | -73.11% | -- |
| Average Basic Shares Outstanding | 103.76% | 101.67% | 69.95% | 45.14% | -- |
| Average Diluted Shares Outstanding | 129.41% | 101.67% | 69.95% | 45.14% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |